Citius Pharmaceuticals (CTXR) Prices 7.058M Share Registered Direct Offering at $1.0625/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall St futures kick off September under pressure as yields, oil prices rise
- Oil up around 2% as renewed US-Iran strikes stoke supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- The Warsh pivot markets didn't expect
- Oil settles up by more than 2.5% as US and Iran resume military attacks
Citius Announces $7.5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
May 14, 2020 9:01 AM EDTCRANFORD, N.J., May 14, 2020 /PRNewswire/ -- Citius Pharmaceuticals, Inc. (Nasdaq: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, today announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase of 7,058,824 shares of its common stock, at a purchase price per share of $1.0625 for gross proceeds of approximately $7.5 million, in a registered direct offering priced at-the-market under Nasdaq rules. Additionally, Citius has also agreed to issue to the investors unregistered warrants... More
